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Abstract
Background: Mice lacking MyoD exhibit delayed skeletal muscle regeneration and markedly enhanced numbers of
satellite cells. Myoblasts isolated from MyoD
-/- myoblasts proliferate more rapidly than wild type myoblasts, display a
dramatic delay in differentiation, and continue to incorporate BrdU after serum withdrawal.
Methods: Primary myoblasts isolated from wild type and MyoD
-/- mutant mice were examined by microarray
analysis and further characterized by cell and molecular experiments in cell culture.
Results: We found that NF-κB, a key regulator of cell-cycle withdrawal and differentiation, aberrantly maintains
nuclear localization and transcriptional activity in MyoD
-/- myoblasts. As a result, expression of cyclin D is maintained
during serum withdrawal, inhibiting expression of muscle-specific genes and progression through the differentiation
program. Sustained nuclear localization of cyclin E, and a concomitant increase in cdk2 activity maintains S-phase
entry in MyoD
-/- myoblasts even in the absence of mitogens. Importantly, this deficit was rescued by forced
expression of IκBαSR, a non-degradable mutant of IκBα, indicating that inhibition of NF-κB is sufficient to induce
terminal myogenic differentiation in the absence of MyoD.
Conclusion: MyoD-induced cytoplasmic relocalization of NF-κB is an essential step in linking cell-cycle withdrawal
to the terminal differentiation of skeletal myoblasts. These results provide important insight into the unique
functions of MyoD in regulating the switch from progenitor proliferation to terminal differentiation.
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Background
Cell survival and differentiation is regulated by NF-κB, a
family of ubiquitously expressed transcription factors
comprising RelA/p65, c-Rel, RelB, p50 (processed form
of p105), and p52 (processed form of p100) [1]. NF-κB
proteins function as homo- or heterodimers, the most
common of which is the p50/p65 heterodimer. All fam-
ily members contain a DNA-binding domain, a protein-
protein dimerization domain, and a nuclear localization
sequence (NLS). However, only RelA/p65, c-Rel, and
RelB have a transactivation domain [2].
Sub-cellular localization of NF-κB is regulated by ‘in-
hibitor of κB’ proteins: IκBα,I κBβ, and IκB [3]. IκB pro-
teins bind NF-κB, mask the nuclear localization signal,
and sequester NF-κB in the cytoplasm as an inactive pro-
tein. Upon induction, IκB kinases (IKKs) phosphorylate
IκB, releasing NF-κB and targeting IκB for degradation.
The released NF-κB enters the nucleus, binds DNA, and
regulates gene transcription. This process is normally
activated by molecules such as cytokines, growth factors,
and bacterial products [4].
Myogenic specification and differentiation requires the
myogenic regulatory factors (MRFs), namely MyoD, Myf5,
myogenin, and MRF4/Myf6 [5]. The MRFs share a highly
homologous basic helix-loop-helix (bHLH) domain, which
is required for DNA binding and dimerization with the
E-protein family of transcription factors. MRF-E-protein
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CANNTG, in gene promoters and regulate transcriptional
activation.
In particular, MyoD and Myf5 are essential for murine
skeletal muscle development [6]. However, mice lacking
MyoD are viable and fertile, and display no overt pheno-
type [7]. This indicates that myogenic specification and
differentiation during embryonic and fetal development
occurs in the absence of MyoD, due to the presence of
other myogenic regulatory factors, such as Myf5. Ana-
lysis of regeneration in MyoD
-/- muscle established an es-
sential role for MyoD in regulating adult myogenesis. In
particular, increased numbers of satellite cells and a defi-
cient muscle regenerative process in mice lacking MyoD
(MyoD
-/-), or MyoD and dystrophin (MyoD
-/-:mdx), sug-
gests that in the absence of MyoD, satellite cells have an
increased propensity for self-renewal [8].
Analysis of the differentiation kinetics of cultured
MyoD
-/- satellite cell derived myoblasts revealed a marked
delay in differentiation, characterized by reduced expres-
sion of differentiation specific markers such as myosin
heavy chain, myogenin, MRF4, α-actins and acetylcholine
receptor-δ [9-11]. Although a portion of MyoD
-/- cells ex-
press myosin heavy chain (MyHC), these myocytes fail to
fuse and remain primarily mononuclear. Moreover, the
majority of MyoD
-/- myoblasts display continued incorpor-
ation of bromodeoxyuridine (BrdU) into DNA after serum
withdrawal, indicating DNA synthesis is maintained in the
absence of mitogen stimulation.
In this study, we examined the role MyoD plays in
regulating cell-cycle withdrawal during terminal differen-
tiation in adult myogenesis by undertaking a closer in-
vestigation of the molecular phenotype of MyoD
-/-
myoblasts. We observed that MyoD
-/- myoblasts main-
tained nuclear localization of NF-κB after serum with-
drawal, and displayed altered expression of NF-κB target
genes. In particular, MyoD
-/- myoblasts failed to down-
regulate cyclin D1, an NF-κB target gene and key medi-
ator of cell-cycle withdrawal and differentiation in myo-
blasts [12,13]. Importantly, inhibition of NF-κB activity,
through expression of a mutant form of IκBα (IκB-SR),
rescued the differentiation of MyoD
-/- myoblasts. There-
fore, we conclude that MyoD controls cell-cycle with-
drawal by regulating the subcellular localization of the
NF-κB family of transcription factors.
Methods
Myoblast isolation and cell culture
Myoblasts were isolated from 6 to 8 week old wild type
(WT) Balb/C mice and MyoD
-/- mice and cultured as pre-
viously described [9]. To induce differentiation, the cells
were washed once with PBS and transferred to differenti-
ation medium (DMEM supplemented with 5% horse
serum (Invitrogen), and 2X penicillin/streptomycin).
C2C12 murine myoblasts were cultured and differentiated
as previously described [14].
Transfections and luciferase assay
C2C12 and MyoD-/- myoblasts were transfected in low
serum Opti-MEM using Lipofectamine (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer. Re-
porter and expression plasmids were previously described
[12], and all transfections were normalized to CMV-βGAL
expression. For luciferase assays, cells were lysed in MPER
(Pierce) and assays were performed as previously described
[12]. MyoD siRNA was obtained from SantaCruz and
transfections were performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA).
RNA isolation and RNase protection assay
RNA was isolated using TriZol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The RNase protection assay was performed
using the RiboQuant kit according to the manufacturer’s
instructions (BD Bioscience, Franklin Lakes, NJ, USA).
The relative amount of radioactivity present in each band
was quantitated using a Phosphorimager (GE Healthcare,
Buckinghamshire, England), and the values obtained for
each cyclin were normalized to the value for the GAPDH
control.
Immunoblotting and antibodies
Proteins were separated on 10% or 12% SDS-polyacrylamide
gel, and transferred to a polyvinylidene fluoride membrane
(Immobilon-P; Millipore, Billerica, MA, USA) according to
established protocols. The antibodies used were all from
Santa Cruz Biotechnology (Santa Cruz. CA, USA): anti- cyc-
lin D1 (C-20), anti-cyclin D2 (H-289), anti-cyclin D3 (C-
16), anti-cdk4 (C-22), anti-cyclin A1 (C-19), anti-cyclin E
(C-19), anti-cdk2 (H-298), anti-cyclin H (C-18), anti-cdk7
(C-19), anti-NF-κB p65 (C-20), anti-Myf5 (C-19), anti-
MyoD (C-20), and anti-IKKγ (FL-419). For immunoblot-
ting, all antibodies were used according to the manufac-
turer’s instructions, normally at a dilution of 1:500 or
1:1,000. Goat anti-mouse and goat anti-rabbit secondary
antibodies were used at 1:2,000 (BioRad, Hercules, CA,
USA). Antibody-bound proteins were detected using
enhanced chemiluminescence (ECL; GE Healthcare,
Buckinghamshire, England) and X-OMAT 5 X-ray film.
Kinase assays
Each 10-cm plate from a differentiation time course of
WT and MyoD
-/- primary myoblasts were lysed with
300 μL of NP-40 Lysis/IP buffer (50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM
DTT, 10% glycerol, 0.1 mM Na2VO3, 50 mM NaF,
20 mM β-glycerophosphate, 50 μg/mL PMSF, 2 μg/mL
leupeptin, 1 μg/mL aprotinin, 10 μg/mL pepstatin).
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histone H1 (Invitrogen) and 5 μCi of γ-
32P-ATP (GE
Healthcare, Buckinghamshire, England) in kinase buffer,
and incubating at 30°C for 20 min. IKK kinase assays
were performed as previously described using a GST-
IκBα substrate [15].
Gene expression analysis
Mouse U74Av2 GeneChip microarrays (Affymetrix, Santa
Clara, CA, USA) were used to analyse gene expression in
wild type and MyoD-/- primary myoblasts [16]. A list of
genes related to the NF-κB pathway was defined with
reference to commercial microarrays (Panomics; Superar-
ray Bioscience, Frederick, MD, USA) and the literature.
Microarray data is available from StemBase (http://www.
scgp.ca:8080/StemBase/) under experiment number E223
(samples S361-4) and E59 (S78-9) and from the National
Center for Biotechnology Information’s Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under series
accession number GSE3245 (GSM73053...64) and
GSE3244 (GSM73026, -29, -32, -35, -38, and -41).
Virus production and transduction
To generate ecotrophic retroviral supernatant, Phoenix-
eco packaging cell lines were obtained from ATCC, cul-
tured in DMEM with 4.5 g/L glucose (Invitrogen Life
Technologies), supplemented with 100 U/mL penicillin
and 100 μg/mL streptomycin, and 10% FBS (Hyclone,
Logan, UT, USA), and transfected either with pBabe/Iκ
(expressing IKBα-SR) or pBabe (empty vector) using lipo-
fectamine 2000 (Invitrogen Life Technologies). Retroviral
supernatant was harvested 48 h after transfection and fil-
tered through a 0.45 μm syringe filter (Millipore). Primary
proliferating MyoD
-/- cells were infected with diluted viral
supernatant plus 8 μg/mL polybrene (hexadimetherine
bromide, Sigma Aldrich, ST. Louis, MO, USA). Drug
Figure 1 NF-κB remains localized to the nucleus after serum withdrawal in MyoD
-/- myoblasts. (A) Protein was isolated from a differentiation
time course of WT and MyoD
-/- primary myoblasts and a western blot using the nuclear (N) and cytoplasmic (C) fractions was performed with an
antibody specific for the p65 subunit of NF-κB. A western blot with an antibody specific for α-tubulin was performed using the cytoplasmic
fractions. (B) Immunofluorescence analysis of WT and MyoD-/- myoblasts and myotubes demonstrate that NF-κB remains localized in the nucleus
in MyoD-/- myoblasts even after differentiation. Staining for NF-κB in red, nuclei are counterstained with DAPI (in blue). Scale bar: 20 μm.
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Aldrich) for 7 days; uninfected controls were obliterated
after 4 days of selection. Differentiation was induced by re-
placing growth medium with DMEM+5% horse serum
(Hyclone).
Animals
All animal procedures conform with the Canadian
Council on Animal Care’s Guide to the Care and Use of
Experimental Animals, the Animals for Research Act,
and were approved by the Animal Care Committee at
University of Ottawa.
Results
Sustained activation of NF-κB during differentiation of
MyoD
-/- myoblasts
MyoD
-/- myoblasts express myosin heavy chain upon
serum withdrawal, yet fail to fuse into multinucleated
myotubes [9]. This phenotype is recapitulated in MyoD-
expressing IκBα-/- fibroblasts, in which NF-κB is persist-
ently nuclear localized [17,18]. Given that NF-κB is nor-
mally relocalized to the cytoplasm during myogenic
differentiation, we sought to determine if NF-κBr e m a i n s
in the nucleus during induction of differentiation in myo-
blasts lacking MyoD. Nuclear and cytoplasmic protein
extracts from a differentiation time course of WT and
MyoD
-/- myoblasts were subjected to western blot analysis
using an antibody specific for p65/RelA. Strikingly,
MyoD
-/- myoblasts displayed continued nuclear localization
of NF-κB (RelA/p65) after mitogen withdrawal, whereas
RelA/p65 was appropriately relocated to the cytoplasm in
WT myoblasts (Figure 1A). Furthermore we conducted im-
munofluorescence analyses of WTand MyoD-/- cells under
growth and differentiation conditions. We observed con-
tinued nuclear localization of NF-κB (RelA/p65) in
MyoD-/- cells during differentiation (Figure 1B) while WT
cells displayed the expected shift in localization of NF-κB
(RelA/p65) during differentiation. Furthermore, MyoD-/-
myoblasts appear to have less cytoplasmic NF-kB than WT
myoblasts in growth conditions, suggesting that NF-κB sig-
nalling is aberrant in the absence of MyoD in proliferation
as well as differentiation.
To determine if continued nuclear localization of p65
correlates with increased transcriptional activity, an NF-
κB specific luciferase reporter (3xκB-Luc) was transfected
into C2C12 cells lacking MyoD expression. C2C12 myo-
blasts transfected with MyoD-specific siRNA (siMyoD-
C2C12) exhibited a significant decrease in MyoD expres-
sion, and resembled MyoD
-/- myoblasts (Figure 2A, data
not shown). Luciferase activity in 3xκB-Luc-transfected
siMyoD-C2C12 myoblasts was increased relative to con-
trol cells, indicating that in the absence of MyoD, RelA/
p65 continued to be transcriptionally active after induc-
tion of differentiation (Figure 2B). Co-transfection with
Figure 2 Loss of MyoD activates NF-κB. (A) Protein isolated from
C2C12 myoblasts transfected with control siRNA or siRNA specific for
MyoD were analyzed by western blot using antibodies specific to
MyoD and α-tubulin. (B) C2C12 cells transfected with control siRNA
(siCont) or MyoD siRNA (siMyoD) were co-transfected with an NF-kB
reporter vector (3xκB-Luc). Bars represent average luciferase activity
(relative light units (RLUs)) (n=3). Error bars represent standard
deviation. (C) Same as B, with the addition of a p65 (NF-κB)
expression vector.
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porter, yet siMyoD cells continued to exhibit elevated
NF-κB activity (Figure 2C).
To determine if expression of NF-κBt a r g e tg e n e s ,o r
genes that participate in the NF-κB signalling pathway,
were altered in the absence of MyoD, the expression pro-
files of MyoD
-/- myoblasts and WT myoblasts were com-
pared using an Affymetrix microarray (Tables 1 and 2)
[16]. Known NF-κB target genes were selected from genes
displaying differences in expression (see http://www.bu.
edu/nf-kb/gene-resources/target-genes/ for an overview).
Genes that were specifically up-regulated in myoblasts
lacking MyoD are tabulated in Table 1, whereas genes that
were down-regulated are documented in Table 2. NF-κB
target genes such as MCP-1/CCL2/GRO-α, MIP-2/CXCL1,
matrix metalloproteinases (MMP3 and MMP13),VCAM1,
IL-6, BCL-2, IL-11, IGFBP-2,a n dJunB are represented in
both Tables 1 and 2, indicating that nuclear localized NF-
κB was transcriptionally active in MyoD
-/- myoblasts. Fur-
thermore we investigated genes involved in myogenesis.
We found the following genes to be down-regulated in
MyoD
-/- myoblasts compared to WT myoblasts: myogenin,
Myf5, Mef2C, embryonic myosin heavy chain, MRF4/
Myf6, as well as Six1.
MyoD
-/- myoblasts maintain expression of cyclin D1 and
D2 after serum withdrawal
MyoD-null myoblasts continue to proliferate in the ab-
sence of mitogens, indicating that cell-cycle modulators,
such as cyclins, may be aberrantly expressed and/or
regulated. Given that RelA/p65 specifically regulates ex-
pression of cyclin D1 in myoblasts we hypothesized that
persistent activation of RelA/p65 would result in contin-
ued expression of cyclin D1 in MyoD
-/- myoblasts, even
after serum withdrawal [12].
In order to investigate changes in important cell-cycle
genes in the absence of MyoD, RNA was isolated from a
differentiation time course of MyoD
-/- and WT primary
myoblasts, and the relative expression level of a variety of
cyclins was determined using an RNase protection assay.
The relative amount of mRNA present for each cyclin was
quantitated using a phosphorimager, and normalized to a
GAPDH control. Figure 3A and 3C show resulting autora-
diographs of polyacrylamide gels, and Figure 3B and 3D
graphically depicts quantitation of the results. MyoD
-/-
myoblasts exhibited a higher level of cyclin D1 and D2
mRNA, and a lower level of cyclin D3 and cyclin G1
mRNA when compared to WT myoblasts (Figure 3A, 3B,
and 3F). However, neither cyclin E nor cyclin H mRNA
was affected by the absence of MyoD (Figure 3C and 3D).
To determine if changes in mRNA expression are
translated into changes in protein levels, nuclear protein
extracts were isolated from a similar differentiation time
course and analyzed by western blot analysis. In accord
with RNase protection assay results, MyoD
-/- myoblasts
displayed a higher level of cyclin D1 and D2 protein in
the nucleus, and continued expression of both cyclins
after mitogen withdrawal (Figure 3E). Expression of cyc-
lin D3 protein, on the other hand, was not altered in the
absence of MyoD. Taken together, these data imply that
persistent activation of RelA/p65 is responsible for ex-
pression of cyclin D1 in MyoD
-/- myoblasts after serum
withdrawal.
pRb is also phosphorylated by cyclin E-cdk2, and this
phosphorylation is required for S-phase entry [19].
Table 1 NF-κB-related genes up-regulated in MyoD
-/-
myoblasts
Gene RefSeq Fold Gene name
Ccl2 NM_011333 166.7 Chemokine (C-C motif) ligand 2
Bgn NM_007542 73.5 Biglycan
Mmp3 NM_010809 34.0 Matrix metallopeptidase 3
Cxcl1 NM_008176 33.0 Chemokine (C-X-C motif) ligand 1
Thbs2 NM_011581 16.9 Thrombospondin 2
Mmp13 NM_008607 9.0 Matrix metallopeptidase 13
Vcam1 NM_011693 8.2 Vascular cell adhesion molecule 1
Il6 NM_031168 8.0 Interleukin 6
Ier3 NM_133662 5.6 Immediate early response 3
Penk1 NM_001002927 4.6 Preproenkephalin 1
Pcaf NM_020005 4.3 p300/CBP-associated factor
H2-T23 NM_010398 3.2 Histocompatibility 2, T region locus 23
Stat6 NM_009284 2.1 Signal transducer and activator of
transcription 6
Ptgs2 NM_011198 2.8 Prostaglandin-endoperoxide synthase 2
Abcb1b NM_011075 2.2 ATP-binding cassette, sub-family B
(MDR/TAP), 1B
Gja1 NM_010288 2.7 Gap junction membrane channel
protein alpha 1
Tnfaip3 NM_009397 2.6 Tumor necrosis factor, alpha-induced
protein 3
Bcl2 NM_009741 2.5 B-cell leukemia/lymphoma 2
Table 2 NF-κB-related genes down-regulated in MyoD
-/-
myoblasts
Gene RefSeq Fold Gene name
Il11 NM_008350 -23.2 Interleukin 11
Igfbp2 NM_008342 -9.1 Insulin-like growth factor binding protein 2
Tlr6 NM_011604 -3.3 Toll-like receptor 6
Fos NM_010234 -3.1 FBJ osteosarcoma oncogene
Ccnd3 NM_007632 -2.7 Cyclin D3
Cd80 NM_009855 -2.3 CD80 antigen
Junb NM_008416 -2.3 Jun-B oncogene
Selp NM_011347 -1.9 Selectin, platelet
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need for cyclin D/cdk4 activity in cell-cycle progression
from G1 to S phase [20,21]. Expression of cyclin E
mRNA was not altered in the absence of MyoD, indicat-
ing that the increase in cyclin D1 expression is not indu-
cing cell-cycle progression through stimulation of E2F
activity on the cyclin E promoter (Figure 3C and D).
However, overexpression of cyclin D1 may also inhibit
MRF activity and myogenic differentiation through a
mechanism independent of pRb or MyoD phosphoryl-
ation [22-24]. Indeed, a hypophosphorylated mutant of
pRb (pRbΔp35; EF), which induces cell-cycle with-
drawal, is unable to rescue cyclin D-dependent inhib-
ition of muscle-specific gene expression (MH Parker,
MA Rudnicki, unpublished observations).
Loss of MyoD stimulates S-phase entry
Although expression of cyclin E mRNA was not altered
(Figure 3C and 3D), western blot analysis of protein
extracts from a differentiation time course of wild type
and MyoD
-/-myoblasts displayed an increased level of
cyclin E protein in the nucleus (Figure 4A). This may
be the result of increased stability of cyclin E protein,
or of prolonged nuclear localization after mitogen
withdrawal. The level of nuclear cdk2 protein was also
elevated, and more importantly, appeared to be the
slower migrating, activated form. In order to determine
if cdk2 activity was maintained after mitogen with-
drawal, a kinase assay was employed using protein
extracts from the same differentiation time course of
wild type and MyoD
-/- myoblasts. As expected, elevated
Figure 3 MyoD
-/- myoblasts maintain cyclin D expression after serum withdrawal. (A, C) RNA was isolated from a differentiation time course
of WT and MyoD
-/- primary myoblasts and an RNase protection assay was performed with the indicated probes. The protected
32P-labeled
fragments were separated on a polyacrylamide gel, the gel dried and exposed to X-ray film. (B, D) The amount of each protected fragment was
quantitated using a phosphorimager. The values obtained were normalized relative to the GAPDH control and the L32 control, and graphed as a
function of the number of days in differentiation medium (DM), n=3. (E) Nuclear protein was isolated from a differentiation time course of WT
and MyoD
-/- primary myoblasts and a western blot was performed with the indicated antibodies. (F) Quantitative real-time PCR for Cyclin D3 of
WT and MyoD-/- myoblasts, n=3.
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activity (Figure 4B).
To determine if increased cdk2 kinase activity forced
cells to enter S-phase more readily, proliferating MyoD
-/-
and WT myoblasts were fixed and analyzed for DNA con-
tent using fluorescence activated cell sorting (FACS). As
expected, MyoD
-/- myoblasts displayed a two-fold increase
in the number of cells in S-phase (23% of MyoD
-/- myo-
blasts compared to 12% of WT myoblasts; Figure 4C). This
increase in the proportion of MyoD
-/- myoblasts in S-phase
was accompanied by a decrease in the proportion of cells
in the G1 phase of the cell cycle (68% of MyoD
-/- cells
compared to 84% of WT cells). Therefore, in the absence
of MyoD, myoblasts enter into S-phase more readily, likely
as a result of increased cyclin E-cdk2 activity.
Inhibition of NF-κB restores differentiation of MyoD
-/-
myoblasts
Skeletal muscle differentiation requires both cell-cycle
withdrawal and muscle-specific gene expression. MyoD
-/-
myoblasts fail to withdraw from the cell cycle, as evidenced
by continued DNA synthesis after induction of differenti-
ation [9]. Given that MyoD-null myoblasts aberrantly
maintain transcriptionally active RelA/p65 after serum
withdrawal, we hypothesize that persistent activation of
RelA/p65 is responsible for the failure to exit the cell cycle.
Moreover, we propose that the inability to induce cell-
cycle withdrawal is directly responsible for the delay in dif-
ferentiation in MyoD
-/- myoblasts.
IκB kinases (IKKs) phosphorylate IκB, resulting in deg-
radation of IκB and nuclear localization of RelA/p65 [3].
Figure 4 MyoD
-/- myoblasts enter S-phase more readily than WT myoblasts. (A) Western blot was performed using the indicated antibodies
and nuclear protein isolated from a differentiation time course of WT and MyoD
-/- primary myoblasts. (B) Cdk2 was immunoprecipitated from
protein extracts of a differentiation time course of WT and MyoD
-/- primary myoblasts, and assayed for kinase activity using histone H1 and
γ-
32P-ATP as substrate. (C) Proliferating WT and MyoD
-/- myoblasts were fixed in ethanol and DNA stained with propidium iodide (PI). Cells were
analyzed for DNA content by FACS analysis. The percentage of cells in each phase of the cell cycle is indicated.
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MyoD-null myoblasts after induction of differentiation,
IKK was immunoprecipitated from MyoD
-/- and wild type
myoblast protein extracts and kinase activity assayed using
GST-IκBα and γ-
32P-ATP as substrate. MyoD-null myo-
blasts displayed approximately 2-fold greater IKK activity,
as compared to WT myoblasts (Figure 5A).
If increased IKK activity results in RelA/p65 activation,
then inhibiting IKK should inhibit NF-κB transcriptional ac-
tivity. Treating MyoD
-/- myoblasts with a chemical inhibitor
of IKK (data not shown), or expressing a dominant negative
mutant of IKKβ (IKKβ DN), resulted in decreased activity
of 3xκB-Luc, indicating that elevated IKK activity is in part
responsible for persistent NF-κB transcriptional activity
(Figure 5A). Therefore, to target RelA/p65 directly, a non-
phosphorylatable mutant form of IκBα (IκBα-SR) was
expressed, which is resistant to targeted degradation and
prevents nuclear localization of NF-κB. Indeed, expression
of IkBα-SR in MyoD
-/- myoblasts inhibited 3xκB-Luc activ-
ity, indicating that NF-κB was directly repressed (Figure 5B).
Moreover, expression of IκBα-SR in MyoD
-/- myoblasts
down-regulated expression of cyclin D1 and cdk2 upon ini-
tiation of differentiation (Figure 6C). This strongly suggests
that sustained nuclear localization of RelA/p65 in the
MyoD-null myoblasts is responsible for cellular proliferation
after serum withdrawal.
Importantly, inhibition of NF-κB activity also induced
expression of myogenin and myosin heavy chain one day
after serum withdrawal, and resulted in the formation of
multinucleated myotubes (Figure 6B to 6D). This is in
contrast to MyoD
-/- myoblasts infected with control
virus, which up-regulated myogenin and myosin heavy
chain to a much lower extent, even 5 days after serum
withdrawal (Figure 6D, DM5). Additionally we examined
the fusion index of myotubes of control and IκBα-SR
expressing MyoD-/- cells at days 3 and 5 after serum
withdrawal. Overexpression of IκBα-SR led to a signifi-
cantly increased fusion index as well as to more differen-
tiation in general (Figure 6B and 6C).
It is interesting to note that IκBαSR-expressing MyoD
-/-
cells up-regulate expression of Myf5 during proliferation
and early differentiation (Figure 6D). Increased expression
of Myf5 may compensate for the lack of MyoD, and may
be responsible for the induction of differentiation specific
genes, such as myogenin and myosin heavy chain, after
cell-cycle withdrawal. This is consistent with the fact that
embryonic and fetal skeletal muscle development is able to
occur in MyoD
-/- mice [7].
Discussion
Finding the specific MyoD-regulated gene product that
links cell-cycle withdrawal and terminal myogenic differ-
entiation has been hitherto elusive. In this study, we dem-
onstrate that continued proliferation and inhibition of
differentiation in MyoD-null myoblasts is due to persistent
nuclear localization of RelA/p65. Expression of a non-
phosphorylatable mutant of IκBα (IκBα-SR), which induces
cytoplasmic retention of RelA/p65, down-regulated ex-
pression of cyclin D1 in MyoD
-/- myoblasts, and resulted
in the formation of multinucleated myotubes. Therefore,
inhibition of RelA/p65 activation was able to substitute
for MyoD expression during myogenic differentiation.
Taken together, this indicates that RelA/p65 provides
the link between MyoD-induced cell-cycle withdrawal
and differentiation.
Figure 5 Elevated IKK activity in MyoD
-/- myoblasts is
responsible for increased NF-κB activity. (A) Kinase assay (KA): IKK
was immunoprecipitated from protein extracts of WT (MyoD
+/+) and
MyoD
-/- primary myoblasts, and assayed for kinase activity using
GST-IκBα and γ-
32P-ATP as substrate. Immunoblot (IB): IKK was
immunoprecipitated from protein extracts of WT (MyoD
+/+) and
MyoD
-/- primary myoblasts, and assayed by western blot using an
antibody specific for IKKγ. (B) MyoD
-/- myoblasts were transfected
with vector control, vector expressing a dominant negative mutant
IKKβ (IKKβ DN) or a non-phosphorylatable mutant of IkBα (IκB-SR), in
addition to an NF-κB reporter (3xκB-Luc). Bars represent average
luciferase activity (relative light units (RLUs)) (n=3). Error bars
represent standard deviation.
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p57, inhibitors of cdk2 and cdk1 kinase activity [25-27].
Moreover, mice lacking p21 and p57 are phenotypically
similar to myogenin knockout mice, in that they lack dif-
ferentiated myofibers [28]. These data suggest that myo-
genic cell-cycle withdrawal and differentiation requires
MyoD-dependent induction of cdk inhibitor expression.
However, MyoD
-/- myoblasts have a similar level of p21
mRNA as compared to WT myoblasts, and mice lacking
p21 display no apparent muscle abnormalities [9,29].
Therefore, we propose that adult satellite cells utilize an
alternate or additional mechanism for inducing cell-cycle
withdrawal during terminal differentiation: down-regula-
tion of RelA/p65 activity.
Notably, MIP-2/CXCL1/GRO-α and IL-6, which were
upregulated 33-fold and 8-fold, respectively, in MyoD
-/-
myoblasts, are associated with constitutive activation of
NF-κB, and promote tumor growth and progression [30].
Importantly, IGFBP-2, which binds IGFs and specifically
inhibits IGF-dependent myogenic cell proliferation, was
down-regulated 9.1-fold in MyoD
-/- myoblasts [31-35].
Therefore, in the absence of MyoD, myoblasts are pro-
grammed to proliferate as a result of maintaining growth
factor signaling. This is consistent with data demonstrat-
ing that MyoD
-/- myoblasts have an increased propensity
for proliferation and self-renewal.
Biglycan and thrombospondin 2, two genes that were up-
regulated in MyoD
-/- myoblasts (73.5-fold and 16.9-fold,
respectively), are extracellular matrix components that
play important roles in scaffolding and signal transduction
during myogenic regeneration. In particular, biglycan binds
TGF-β, and plays an important role in mediating TGF-β
signaling in responding cells [36,37]. This is important
given that TGF-β inhibits myogenic differentiation and
induces expression of cyclin D1 [22]. Taken together, these
data strongly suggest that NF-κB regulates expression of
genes important for inducing cell proliferation.
During normal differentiation of myoblasts, NF-κBi s
relocalized to the cytoplasm and DNA-binding activity
decreases within 24 h of serum withdrawal [12,18]. Differ-
entiation is accelerated in myoblasts expressing a non-
phosphorylatable form of IκBα (IκBαSR), which is unable
to be degraded, thus inhibiting NF-κB (p65) nuclear
localization [12]. Furthermore, these IκBαSR-expressing
myoblasts proliferate less rapidly and down-regulate ex-
pression of cyclin D1. In contrast, IκBα
-/- mouse embry-
onic fibroblasts (MEFs) infected with a MyoD-expressing
retrovirus maintain NF-κB nuclear localization, resulting
in the formation of fewer myotubes that are smaller and
incorporate fewer nuclei [17]. Our experiments explain
mechanistically why MyoD-null myoblasts display a
phenotype similar to that of MyoD-infected IκBα
-/- MEFs.
During myogenic regeneration, satellite cells are acti-
vated and proliferate prior to initiating differentiation.
Increased numbers of satellite cells and a deficient
muscle regenerative process in MyoD
-/- mice suggest that
in the absence of MyoD, satellite cells have an increased
propensity for self-renewal rather than differentiation
[38]. In light of the data presented here, we conclude
that RelA/p65 plays an important role during the myo-
blast to myotube transition during adult myogenesis. In-
deed, treatment of mdx mice with a cell permeable
peptide inhibitor of IKK, which specifically inhibits NF-
κB activity, restores regeneration, as evidenced by a
greater number of newly formed myofibers, and
increased muscle tetanic force [39].
Failure to induce myogenic differentiation is also illu-
strated in rhabdomyosarcoma (RDS), one the most com-
mon childhood solid tumors. RDS is characterized by
inhibition of MyoD activity and concomitant failure to
withdraw from the cell cycle and differentiate. This
study suggests that loss of MyoD activity in RDS cells
may cause aberrant nuclear localization of NF-κB,
resulting in sustained cyclin D1 expression. As such,
inhibiting IKK and stabilizing IκBα may play a valuable
role in inhibiting proliferation and inducing differenti-
ation in RDS cells.
During myogenesis, cytoplasmic re-localization of
RelA/p65 after mitogen withdrawal plays a key role for
down-regulating cyclin D expression, inducing cell-cycle
withdrawal and activating differentiation-specific gene
expression. Therefore, the regulation of NF-κB is essen-
tial in the induction of myogenic differentiation. Our
experiments define the mechanistic link between MyoD
and NF-κB that acts to couple cell-cycle withdrawal to
terminal differentiation.
Figure 6 Nuclear localization of NF-κB inhibits terminal differentiation. (A) MyoD
-/- myoblasts were infected with empty capsid (pBABE) or
virus expressing IκBα-SR (pBABE-IkB). Protein extracts from proliferating infected cells and uninfected cells (control) were analyzed by western blot
analysis using an antibody specific to IκBα. (B) MyoD
-/- myoblasts were infected with empty capsid (pBABE) or virus expressing IκBα-SR (pBABE-
IkB). Proliferating cells (GM), or cells induced to differentiate for 5 days, were fixed and assessed for myosin heavy chain (MyHC) expression (in
green). Nuclei were visualized using DAPI (in blue). (C) Fusion index of myotubes from MyoD
-/- cells either infected with a control (pBABE) or an
IκBα-SR (pBABE-IkB) expressing virus, n=5, **=P<0.01, ***=P<0.001. (D) MyoD
-/- myoblasts were infected with empty capsid (pBABE) or virus
expressing IκBα-SR (pBABE-IkB). Protein extracts from a differentiation time course of infected and uninfected cells were analyzed by western blot
analysis using the antibodies indicated.
(See figure on previous page.)
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We have demonstrated that NF-κB, a key regulator of
cell-cycle withdrawal and differentiation, aberrantly
maintains nuclear localization and transcriptional activity
in MyoD
-/- myoblasts. Cyclin D is consequently main-
tained during serum withdrawal, inhibiting progression
through myogenic differentiation. Sustained nuclear
localization of cyclin E, and a concomitant increase in
cdk2 activity maintains S-phase entry in MyoD
-/- myo-
blasts even in the absence of mitogens. Forced expres-
sion of IκBαSR, a non-degradable mutant of IκBα,
rescued the deficit indicating that inhibition of NF-κBi s
sufficient to induce terminal myogenic differentiation.
Therefore, MyoD-induced cytoplasmic relocalization of
NF-κB is an essential step in linking cell-cycle with-
drawal to terminal differentiation.
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